Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23902068 | 0.85 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL26680172 | 0.78 | MEN1 (0.39) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL17553434 | 0.78 | ALDH1A1 (0.30) | MEN1KMT2A | |
| SCHEMBL20960872 | 0.78 | MEN1 (0.39) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL25152955 | 0.78 | ALDH1A1 (0.33) | MEN1KMT2A | |
| SCHEMBL5395924 | 0.77 | MEN1 (0.37) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL21146711 | 0.75 | — | — | |
| SCHEMBL23902157 | 0.74 | MEN1 (0.37) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL24246819 | 0.74 | — | — | |
| SCHEMBL14509766 | 0.72 | ALDH1A1 (0.37) | CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | MEN1 574/4885CYP3A4 3461/4885ALOX15 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.